Effect of bezafibrate on monocyte cytokine release and systemic inflammation in patients with impaired fasting glucose

Journal of Clinical Pharmacology

Volumn 51, Issue 10, 2011, Pages 1459-1467

  Krysiak, Robert ^a   Okopien, Boguslaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Bezafibrate; impaired fasting glucose; low grade inflammation; mixed dyslipidemia; monocytes

Indexed keywords

BEZAFIBRATE; C REACTIVE PROTEIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PROTEIN BLOOD LEVEL;

BEZAFIBRATE; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CYTOKINES; DYSLIPIDEMIAS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MONOCYTES;

EID: 80053277292     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010382914     Document Type: Article

References (40)

1. Balakumar P, Rose M, Singh M. PPAR ligands: are they potential agents for cardiovascular disorders?. Pharmacology. 2007 ; 80: 1-10 (Pubitemid 47013361)
2. Wierzbicki AS. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Curr Opin Cardiol. 2009 ; 24: 372-379
3. Keating GM, Croom KF. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007 ; 67: 121-153 (Pubitemid 46105094)
4. Okopien B, Haberka M, Madej A, et al. Extralipid effects of micronized fenofibrate in dyslipidemic patients. Pharmacol Rep. 2006 ; 58: 729-735 (Pubitemid 44741692)
5. Okopien B, Kowalski J, Krysiak R, et al. Monocyte suppressing action of fenofibrate. Pharmacol Rep. 2005 ; 57: 367-372 (Pubitemid 41030697)
6. Okopien B, Krysiak R, Haberka M, Herman ZS. Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary hypercholesterolemia. J Cardiovasc Pharmacol. 2005 ; 45: 314-320 (Pubitemid 40411286)
7. Okopien B, Krysiak R, Kowalski J, et al. Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J Cardiovasc Pharmacol. 2005 ; 46: 377-386 (Pubitemid 41262842)
8. Krysiak R, Labuzek K, Okopien B. Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep. 2009 ; 60: 1134-1145
9. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 1998 ; 393: 790-793 (Pubitemid 28299490)
10. Xu X, Otsuki M, Saito H, et al. PPARalpha and GR differentially down-regulate the expression of nuclear factor-kappaB-responsive genes in vascular endothelial cells. Endocrinology. 2001 ; 142: 3332-3329
11. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood. 2003 ; 101: 545-551 (Pubitemid 36077576)
12. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis. 2003 ; 170: 315-323
13. Sebestjen M, Keber I, Zegura B, et al. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb Haemost. 2004 ; 92: 1129-1135 (Pubitemid 39545539)
14. Undas A, Celi ska-Lowenhoff M, Domagała TB, et al. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost. 2005 ; 94: 193-199 (Pubitemid 40974724)
15. Madej A, Okopień B, Kowalski J, et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther. 1998 ; 36: 345-349 (Pubitemid 28271555)
16. Manninen V, Tenkanen L, Koskinen , et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992 ; 85: 37-45
17. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med. 2002 ; 162: 2597-2604 (Pubitemid 35453499)
18. de Faire U, Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials. Cardiovasc Drugs Ther. 1997 ; 11 (suppl 1). 257-263 (Pubitemid 27229321)
19. Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes: a double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998 ; 21: 641-648 (Pubitemid 28172949)
20. Goldenberg I, Benderly M, Goldbourt U. Update on the use of fibrates: focus on bezafibrate. Vasc Health Risk Manag. 2008 ; 4: 131-141 (Pubitemid 351460854)
21. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006 ; 29: 1130-1139 (Pubitemid 44115261)
22. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust. 2007 ; 186: 461-465 (Pubitemid 46806823)
23. Okopien B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab. 2006 ; 91: 1770-1778
24. Krysiak R, Stachura-Kulach A, Okopien B. Metabolic and monocyte-suppressing action of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism abnormalities. Pharmacol Rep. 2010 ; 62: 127-137
25. Davidson M. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol. 2008 ; 102 (12A). 19L-27L
26. Kher N, Marsh JD. Pathobiology of atherosclerosis-a brief review. Semin Thromb Hemost. 2004 ; 30: 665-672
27. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006 ; 86: 515-581
28. Kinlay S, Egido J. Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol. 2006 ; 98: 2P-8P
29. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev. 2007 ; 65 (12 pt 2). S253-S259
30. Cannon CP. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. Am J Cardiol. 2008 ; 102: 5L-9L
31. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost. 2009 ; 7 (suppl 1). 328-331
32. Wilson HM, Barker RN, Erwig LP. Macrophages: promising targets for the treatment of atherosclerosis. Curr Vasc Pharmacol. 2009 ; 7: 234-743
33. Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation. 2003 ; 107: 1733-1737 (Pubitemid 36418352)
34. Keech A, Simer RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 ; 366: 1849-1861
35. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 ; 362: 1563-1574
36. Pruski M, Krysiak R, Okopien B. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care. 2009 ; 32: 1421-1424
37. Soderberg S, Zimmet P, Tuomilehto J, et al. High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius. J Intern Med. 2004 ; 256: 37-47 (Pubitemid 38813618)
38. Keating GM, Croom KF. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007 ; 67: 121-153 (Pubitemid 46105094)
39. Gouni-Berthold I, Krone W. Peroxisome proliferator-activated receptor alpha (PPARalpha) and atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord. 2005 ; 5: 513-523
40. Okopien B, Krysiak R, Kowalski J, et al. The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis. 2004 ; 176: 327-335 (Pubitemid 39369523)